Japan Readies One-Off Price Cuts For Big Sellers

Entresto Slashed By 15%

Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.

The market expansion repricing was applied to five products.
market expansion repricing applied to five products • Source: Shutterstock

Following the latest round of of annual drug reimbursement price cuts announced in March and implemented in April, Japanese regulatory authorities have now announced additional extraordinary price revisions for five products, effective 1 August.

Daiichi Sankyo Co., Ltd.’s Tarlige (mirogabalin) and Viatris Inc.’s Lyrica (pregabalin), both neuropathic pain drugs, along with

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By 

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By 

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

Progress Or Hype? Looking At A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting reimbursement prices. How has the sector panned out over the last decade?

Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices

 
• By 

A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.

More from Asia

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By 

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By 

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.